Your Patients Need Abrilada — Here's How to Help Them Get It

When you prescribe Abrilada (Adalimumab-afzb) for a patient with rheumatoid arthritis, Crohn's disease, psoriasis, or another autoimmune condition, the last thing you want to hear is that they couldn't fill it. But in the complex world of specialty biologics in 2026, that's exactly what many providers are hearing from their patients.

This guide gives you practical, actionable steps to help your patients locate and access Abrilada — and what to do when they can't.

Current Abrilada Availability

Abrilada is not in shortage from a manufacturing standpoint. Pfizer continues to produce and distribute it. However, real-world availability is shaped by:

• Specialty pharmacy networks: Abrilada requires cold-chain storage and is dispensed through specialty pharmacies, not retail locations. Not all specialty pharmacies stock every adalimumab biosimilar.
• PBM formulary decisions: Major pharmacy benefit managers have consolidated their adalimumab formularies. The biosimilar preferred on a patient's plan determines which product the specialty pharmacy will stock and dispense.
• Market fragmentation: With 10+ adalimumab biosimilars available, distribution is spread across many products. Individual pharmacies may only carry 2 or 3 options.

For a deeper analysis, see our provider briefing on Abrilada availability.

Why Your Patients Can't Find Abrilada

When patients call your office saying they can't get their Abrilada, the root cause usually falls into one of these categories:

Insurance Doesn't Cover It

The most common issue. The patient's plan may prefer Hadlima, Cyltezo, Hyrimoz, or another biosimilar. Even with an interchangeable designation, if Abrilada isn't on the formulary, the patient may face a higher co-pay or outright denial.

Pharmacy Doesn't Stock It

Even when insurance covers Abrilada, the patient's designated specialty pharmacy may not carry it. This is common when the pharmacy is aligned with a PBM that prefers a different product.

Prior Authorization Pending

Many plans require prior authorization for adalimumab products. If the PA hasn't been submitted or approved, the pharmacy can't dispense the medication.

Patient Cost Barrier

With specialty tier co-pays ranging from $50 to $500+ per fill, some patients abandon prescriptions at the pharmacy counter. They may not know about savings programs that could dramatically reduce their costs.

What Providers Can Do: 5 Steps

Step 1: Check the Patient's Formulary Before Prescribing

The single most impactful thing you can do is verify which adalimumab product is preferred on the patient's plan before writing the prescription. This prevents delays, denials, and frustration.

How to check:

• Use your EHR's formulary lookup tool if available
• Call the patient's insurance (number on the back of their card)
• Contact Pfizer enCompass at 1-844-722-6672 for benefits verification

Step 2: Submit Prior Authorization Proactively

Don't wait for a denial to trigger a PA request. If you know the patient's plan requires prior authorization for biologics, submit it at the time of prescribing. This can shave days or weeks off the access timeline.

Tips for faster PA approval:

• Use electronic prior authorization (ePA) through your EHR when available
• Include relevant clinical documentation upfront (diagnosis, prior treatments tried, lab results)
• Note if the patient has already tried and failed step-therapy requirements

Step 3: Use Medfinder to Locate a Stocking Pharmacy

Medfinder for providers lets you or your staff search for pharmacies that have Abrilada in stock in real time. Instead of calling pharmacy after pharmacy, you can quickly identify where to direct your patient.

This is especially useful when:

• The patient's usual specialty pharmacy doesn't carry Abrilada
• You need to find an alternative pharmacy quickly to prevent a treatment gap
• A patient is traveling or relocating and needs to find a new pharmacy

Step 4: Connect Patients with Financial Assistance

Many patients don't know about the savings programs available to them. Take a moment to inform patients about:

• Pfizer enCompass Co-Pay Assistance: $4,000 to $14,000 per year for eligible commercially insured patients. Not available for government insurance (Medicare, Medicaid, Tricare).
• Pfizer Patient Assistance Program (RxPathways): Free Abrilada for eligible uninsured or underinsured patients who meet income requirements.
• NeedyMeds.org and RxAssist.org: Independent databases of patient assistance programs.

Your office staff or a dedicated patient navigator can help with enrollment. Call 1-844-722-6672 to get started.

Step 5: Have a Backup Plan Ready

Sometimes Abrilada just isn't going to work for a particular patient's insurance situation. Have a backup plan:

• Know which 2–3 adalimumab biosimilars are most commonly covered by your patients' major payers
• Keep a quick-reference list of interchangeable biosimilars: Cyltezo, Hadlima, Hyrimoz, Amjevita, Hulio, Simlandi
• Be ready to switch prescriptions quickly to prevent treatment gaps

For details on available alternatives, see alternatives to Abrilada.

Alternatives to Consider

If Abrilada isn't accessible for a specific patient, these interchangeable adalimumab biosimilars have the same mechanism, indications, and dosing:

• Cyltezo (Adalimumab-adbm): Boehringer Ingelheim. Citrate-free. Also available as unbranded adalimumab-adbm at lower price.
• Hadlima (Adalimumab-bwwd): Samsung Bioepis/Organon. Widely available on many formularies.
• Hyrimoz (Adalimumab-adaz): Sandoz. Citrate-free. SensoReady Pen device.
• Amjevita (Adalimumab-atto): Amgen. Available in standard and high-concentration formulations.

All have demonstrated clinical equivalence to Humira in phase III studies, and switching between products is supported by FDA interchangeability data.

Workflow Tips for Your Practice

Streamline biologic access for your practice with these workflow strategies:

Designate a Biologic Access Lead

Assign one staff member (nurse, MA, or patient navigator) to manage biologic prescriptions, including PA submissions, insurance verification, and patient support program enrollment. This prevents tasks from falling through the cracks.

Build a Biosimilar Quick-Reference Sheet

Create an internal reference with:

• All available adalimumab products and their interchangeable status
• Which products are preferred by your patients' top 3–5 insurance plans
• Contact information for each manufacturer's support program
• Links to Medfinder for real-time availability checks

Set Up Automated PA Workflows

If your EHR supports it, create templates or order sets that automatically trigger prior authorization workflows when a biologic is prescribed. This reduces manual effort and speeds up approval.

Schedule Follow-Up Within 2 Weeks of Prescribing

For new biologic starts, schedule a brief check-in (phone, portal message, or visit) within 2 weeks of prescribing. This catches access problems early, before the patient has gone weeks without treatment.

Final Thoughts

Helping patients access Abrilada in 2026 requires a proactive approach. By checking formularies upfront, submitting PAs early, using tools like Medfinder, connecting patients with financial assistance, and having backup biosimilar options ready, you can minimize treatment gaps and keep your patients on track.

The adalimumab biosimilar landscape is complex, but the clinical outcome is what matters most: getting your patients the TNF inhibitor therapy they need, regardless of which specific product ends up in the syringe.

For cost-saving strategies to share with patients, see our patient savings guide. For the provider perspective on helping with costs, see our provider's guide to helping patients save.